Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Clinical Research Bill Passes Lower House
March 23, 2017
- MHLW Orders Label Revisions for 44 APIs in Sleep/Anxiolytic/Epilepsy Agents
March 21, 2017
- MHLW Unveils Revised Label Format; Notification Due Out Early FY2017
March 21, 2017
- MHLW Ordinance Will Close Loopholes in Clinical Research Bill’s Funding Disclosure Rules: Bureau Chief
March 21, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Japan Healthcare Spending Logs Slight Rise on Subdued Hep C Sales in April-September
March 17, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Recovering Trust in Clinical Research Is Urgent Task: Shiozaki
March 17, 2017
- MHLW Panel Initiates Discussions on Whether to Lift Ban on Export of Blood Products
March 17, 2017
- AMED Begins Taking Applications for Funding for Drug Discovery Environments
March 17, 2017
- Optimal Use Guidelines for Additional Indications to Be Reported to Chuikyo after Issuance
March 16, 2017
- Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
- Chuikyo Subcommittee OKs 5-Scale Rating for Cost Effective Assessments
March 16, 2017
- Spontaneous Reporting Required Even When Causal Relationship Is Unclear: MHLW
March 16, 2017
- Chuikyo Approves Optimal Use Promotion Guidelines for Repatha, Praluent
March 16, 2017
- Ex-Minister Tamura, 17 Healthcare Leaders to Launch Study Group
March 15, 2017
- MHLW to Up Ante on Drug Distribution, Launch Panel on March 29: Minister
March 15, 2017
- PMDA’s FY2017 Project Plan Sets Higher Goal for Standard Product Review
March 15, 2017
- PMDA Approves Draft Budget for FY2017
March 15, 2017
- PMDA’s Steering Committee Discusses Fines, Regulatory Revision in Wake of Kaketsuken Scandal
March 15, 2017
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…